Rewrite this news in-house style based on British English without Plagiarism, remove direct speeches, and Use simple and uncomplicated language as far as possible.
Thursday, June 11, 2026
Orionis Biosciences has entered into an expanded multi-year collaboration with Novartis to discover and develop molecular glue medicines targeting difficult-to-treat diseases across multiple therapeutic areas.
The agreement builds on the existing relationship between the two companies and aims to advance the use of induced proximity approaches in drug discovery. Under the collaboration, Orionis and Novartis will use Orionis’s Allo-Glue™ platform together with its artificial intelligence-driven discovery engine to accelerate target identification, ligase profiling and molecular glue optimisation.
The combined technologies are designed to support the systematic discovery of small-molecule molecular glues, which work by bringing proteins into close proximity to modify biological processes and influence disease-related targets.
As part of the agreement, Orionis will receive an upfront payment of USD 40 million. The company is also eligible to receive up to USD 1.4 billion in research, development and commercial milestone payments, in addition to tiered royalties on future product sales arising from the collaboration.
The expanded partnership reflects continued confidence in Orionis’s molecular glue platform and its progress in developing scalable and rational approaches for discovering this emerging class of medicines.
Orionis noted that recent advances in artificial intelligence and robotic automation have improved several stages of molecular glue discovery, including identifying productive target-ligase pairs and optimising potential drug candidates. These developments have helped strengthen the platform’s capabilities and support larger collaborative programmes.
The companies will explore the potential of molecular glue technologies across a range of therapeutic areas, with the goal of expanding the number of biological targets that can be addressed through future treatments.
Source: orionisbio.com
